Videos

/sg/oncology/giotrif/efficacy/afatinib-treatment-nsclc-harbouring-uncommon-egfr

2:40
Video: Uncommon EGFR pooled analysis in 693 patients
/sg/metabolic/empagliflozin/when-time-meets-power/wtmp-25-years-possibilities-dda

0:40
WTMP 2.5 Years of possibilities DDA
/sg/oncology/giotrif/expert-conversations/a-real-world-experience

19:15
Effectiveness of Dose Modification Strategies with Afatinib: A Real-World Experience
/sg/oncology/giotrif/expert-conversations/egfr-tki-related-dermatological-adverse

21:28
EGFR TKI-related Dermatological Adverse Events
/sg/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive-video

3:05
Video: GioTag Final Analysis
/sg/oncology/giotrif/expert-conversations/lecture-series/giotag-asian-data-and-giotag-japan

02:54
GioTag Asian data and GioTag Japan
/sg/oncology/giotrif/expert-conversations/lecture-series/notable-osimertinib-efficacy-after-afatinib

04:05
Notable osimertinib efficacy after afatinib
/sg/oncology/giotrif/expert-conversations/lecture-series/importance-t790m-testing-methods-and-rebiopsy

02:15
Importance of T790M testing methods and rebiopsy
/sg/oncology/giotrif/expert-conversations/lecture-series/afatinib-takes-all-uncommon-mutation

04:17
Afatinib takes all in uncommon mutation
/sg/oncology/giotrif/expert-conversations/lecture-series/patient-profiles-consider-sequencing-approach

02:20
Patient profiles to consider a sequencing approach
/sg/oncology/giotrif/expert-conversations/tumour-heterogeneity-lung-cancer-asian-setting

28:37
Tumour Heterogeneity in Lung Cancer - Asian Setting
/sg/oncology/giotrif/expert-conversations/treatment-strategy-egfr-tkis-asian-setting

25:25
Treatment Strategy with EGFR-TKIs Asian Setting
/sg/cardiovascular/dabigatran-etexilate/safety/life-happens-football-fan

01:44
Life Happens - Football fan
/sg/cardiovascular/dabigatran-etexilate/safety/life-happens-fisherman

01:35
Life Happens - Fisherman
/sg/cardiovascular/dabigatran-etexilate/safety/life-happens-artist

01:43
Life Happens - Artist
/sg/cardiovascular/dabigatran-etexilate/safety/professor-john-eikelboom-dabigatran-patients

03:22
Professor John Eikelboom on dabigatran patients with cardiovascular comorbidities
/sg/cardiovascular/dabigatran-etexilate/safety/pradaxa-patient-journey

01:43
Pradaxa patient journey
/sg/cardiovascular/dabigatran-etexilate/reversibility/doctors-testimonial

03:40
Doctor's testimonial
/sg/cardiovascular/dabigatran-etexilate/safety/patients-testimonial

02:54
Patient's testimonial
/sg/cardiovascular/dabigatran-etexilate/safety/gloria-af-infographic

02:45
GLORIA-AF Infographic
/sg/cardiovascular/dabigatran-etexilate/safety/gloria-af

05:56
GLORIA-AF
/sg/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-2-pci

03:07
RE-DUAL PCI subgroup - Expert Q&As part 2 - PCI complexity
/sg/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-2-landmark

04:08
RE-DUAL PCI subgroup - Expert Q&As part 2 - Landmark analysis
/sg/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-2-age

03:15
RE-DUAL PCI subgroup - Expert Q&As part 2 - Age
/sg/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-1

02:46
RE-DUAL PCI subgroup - Expert Q&As part 1 ACS Q1
/sg/cardiovascular/dabigatran-etexilate/safety/atrial-fibrillation

04:32
Atrial Fibrillation
/sg/cardiovascular/dabigatran-etexilate/safety/re-ly-landmark-study-world-cardiology

02:32
RE-LY (A Landmark Study in The World of Cardiology)
/sg/cardiovascular/dabigatran-etexilate/safety/differences-between-re-dual-pci-pioneer-af-pci

01:49
Differences between RE-DUAL PCI & PIONEER AF-PCI
/sg/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-acs-and-p2y12-subgroup-analysis

03:08
RE-DUAL PCI with ACS and P2Y12 Subgroup Analysis
/sg/cardiovascular/dabigatran-etexilate/safety/dabigatran-elderly-patients-renal-impairment

03:08
Dabigatran in elderly patients with renal impairment
/sg/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-renal-function-subgroup-analysis

02:25
RE-DUAL PCI Renal Function Subgroup Analysis
/sg/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-ttr-subgroup-analysis

02:37
RE-DUAL PCI TTR Subgroup Analysis
/sg/cardiovascular/dabigatran-etexilate/reversibility/life-happens-100636

01:43
Life Happens
/sg/cardiovascular/dabigatran-etexilate/reversibility/life-happens-100635

01:42
Life Happens
/sg/cardiovascular/dabigatran-etexilate/reversibility/life-happens-100634

01:43
Life Happens
/sg/cardiovascular/dabigatran-etexilate/reversibility/life-happens-100627

03:29
Life Happens
/sg/metabolic/empagliflozin/webinar/summary-hope-journey-towards-empa-reg-outcome

04:22
SUMMARY- Before hope: A journey towards EMPA-REG OUTCOME
/sg/metabolic/empagliflozin/webinar/hope-journey-towards-empa-reg-outcome

27:31
Before hope: A journey towards EMPA-REG OUTCOME
/sg/cardiovascular/telmisartan/blood-pressure-control/blood-pressure-control-view-prof-bryan-william

07:56
Prof Bryan William on BP control
/sg/metabolic/linagliptin/efficacy/patient-case-2-achieving-optimal-management

21:17
Patient case 2: Achieving optimal management in an elderly patient with declining renal function
/sg/metabolic/linagliptin/efficacy/patient-case-1-achieving-optimal-management

23:02
Patient case 1: Achieving optimal management while considering poor treatment compliance and renal function decline
/sg/metabolic/linagliptin/efficacy/trajenta-benefits-proven-efficacy-ease-use-one

00:46
Trajenta® benefits: Proven efficacy, ease of use
/sg/metabolic/empagliflozin/experts-interview/asian-forum-2018-how-have-recent-cv-outcome-trials

03:48
Asian CardioDiabetes Forum 2018 - How have recent CV outcome trials influence clinical practice by Dr. Neale Cohen
/sg/metabolic/empagliflozin/experts-interview/asian-forum-2018-role-cardiologist

03:51
Asian CardioDiabetes Forum 2018 - The role of a cardiologist in diabetes management by Dr. Mansoor Husain
/sg/metabolic/linagliptin/dosing/simplicity-trajenta-within-dpp4i-class

01:03
Simplicity of Trajenta® within the DPP4i class: Established efficacy, established safety profile, and convenience of one dose once daily
/sg/metabolic/linagliptin/dosing/trajenta-simple-way-keep-your-patients-licensed

01:07
Trajenta®: A simple way to keep your patients on a licensed dose when administered as appropriate: 5 mg OD
/sg/metabolic/linagliptin/dosing/trajenta-makes-life-easier-gps-well-patients

00:55
Trajenta® makes life easier for GPs as well as patients
/sg/respiratory/spiolto/respimat/respimat-delivers-drug-actively

03:29
Respimat delivers drug actively without the need of COPD patients to forcefully inhale
/sg/metabolic/empagliflozin/experts-interview/asian-forum-2018-why-it-important-examine-evidence

02:28
Asian CardioDiabetes Forum 2018 - Why is it important to examine evidence and not assume class effect by Prof. Richard Donnelly
/sg/respiratory/spiolto/guidelines/gold-2019-role-lama-laba

01:49
GOLD 2019 - Role of LAMA/LABA
/sg/respiratory/spiolto/guidelines/gold-update-2019

08:30
GOLD Update 2019
/sg/respiratory/spiolto/respimat/importance-particle-size

01:17
Respimat® produces a soft mist of high fine particle fraction aerosol which delivers Spiolto® deep into patients' lungs
/sg/respiratory/spiolto/respimat/how-assemble

01:23
Respimat® Device Assembly - Preparation for First Use
/sg/respiratory/spiolto/respimat/how-use

00:51
Preparing Respimat® for Daily Use
/sg/respiratory/spiolto/efficacy/treatment-lamalaba-vs-lamalabaics

02:02
WISDOM trial suggests only a minority of COPD patients benefit from the addition of an ICS on top of SPIRIVA+LABA, and these are clearly identifiable
/sg/respiratory/spiolto/efficacy/treatment-lamalaba-vs-labaics

01:35
ENERGITO and FLAME demonstrate consistent superiority with LAMA/LABA vs LABA/ICS for all outcomes related to lung function, symptom control and exacerbations
/sg/respiratory/spiolto/efficacy/early-intervention-optimize-lung-function

02:13
Early intervention to optimize lung function
/sg/metabolic/empagliflozin/cv-risk-protection/what-are-main-considerations-when-choosing-medication

02:48
What are the main considerations when choosing a medication for patients with type 2 diabetes?
/sg/metabolic/empagliflozin/cv-risk-protection/are-patients-t2d-elevated-cv-risk

02:19
Are patients with T2D at elevated CV risk?
Load more